In vivo dosimetry with diodes in rectal cancer patients

Strojnik, A.

doi:10.2478/v10019-007-0031-8

Cited by 4 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this method in the patient study involving 25 cervical cancer patients is comparable with the results obtained with other in-vivo dosimeters. The standard deviation of ±2.9% along with mean dose reported by Mortan JP et al [14] using MOSFET for pelvis patients, SD of ±1.4% reported by Andrej Strojnik [15] using diodes and SD of ±2.6% by Alessandro M.Costa using TLD [16] are comparable with the SD values obtained in this study. Gandhi MA et al [17] using diodes in rectal cancer have shown that 86.493% of measurements are within ±3%, are comparable with our results of 83.2% for individual measurements and 92% for the average dose for 5 fractions.…”

Section: Resultssupporting

confidence: 90%

Estimation of midpoint dose for cervical cancer patients using EPID

Balan

Chandrasekaran

Ramasubramanian

et al. 2018

Polish Journal of Medical Physics and Engineering

View full text Add to dashboard Cite

Purpose: To estimate the midpoint dose delivered to cervical cancer patients treated by conventional technique using Electronic Portal Imaging Device (EPID). Materials and Methods: Clinac 2100 equipped with aS500 EPID was used in this study. A methodology was developed to generate a Gy/Calibration Unit (CU) look up table for the determination of midpoint dose of patients. 25 patients of cervical cancer were included in this study and the delivered dose to the midpoint of the patients was estimated using EPID. The deviation between the prescribed and the measured dose was calculated and analysed. Results: EPID showed a linear response with increase in Monitor unit and the Gy/CU look up table was validated for different field sizes and depth. 250 fields were measured for 25 patients, 10 measurements per patient, weekly once and for 5 weeks. The results show that out of 250 measurements, 98% of the measurements are within ±5% and 83.2% are within ±3% for with a standard deviation of 1.66%. Conclusion: The outcome of this study proves the efficacy of this methodology for the estimation of midpoint dose using EPID with minimal effort, time and without any inconvenience to the patients unlike other in-vivo dosimeters.

show abstract

Section: Resultssupporting

confidence: 90%